What Dermira, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Pena Luis C. | Chief Development Officer | Feb 20 | Disposition to Issuer · D | −18,233 | $18.75 | −$342K | 0 |
| Horan Christopher | Chief Technical Ops Officer | Feb 20 | Disposition to Issuer · D | −21,400 | $18.75 | −$401K | 0 |
| Aurora Daljit Singh | Chief Scientific Affairs Off | Feb 20 | Disposition to Issuer · D | −30,089 | $18.75 | −$564K | 0 |
| Fust Matthew K | Director | Feb 20 | Disposition to Issuer · D | −5,051 | $18.75 | −$94.7K | 0 |
| Cohen David E | Director | Feb 20 | Disposition to Issuer · D | −35,682 | $18.75 | −$669K | 0 |
| Guggenhime Andrew | CFO | Feb 20 | Disposition to Issuer · D | −41,951 | $18.75 | −$787K | 0 |
| Wiggans Thomas G | CEO & Chairman of the Board | Feb 20 | Disposition to Issuer · D | −180,985 | $18.75 | −$3.39M | 0 |
| Wiggans Thomas G | CEO & Chairman of the Board | Feb 20 | Disposition to Issuer · D | −49,963 | $18.75 | −$937K | 0 |
| Nunn Jason Raleigh | Director | Feb 20 | Disposition to Issuer · D | −6,000 | $18.75 | −$113K | 0 |
| Lyons-Williams Lori | Chief Commercial Officer | Feb 20 | Disposition to Issuer · D | −25,401 | $18.75 | −$476K | 0 |
| Bald Eagle Acquisition Corp | 10% owner | Feb 20 | Open-market buy · P | +40,926,025 | $18.75 | +$767M | 100 |
| Sebelius Kathleen | Director | Feb 20 | Disposition to Issuer · D | −6,000 | $18.75 | −$113K | 0 |
| Griffith Christopher M. | Chief Business & Strategy Off | Feb 20 | Disposition to Issuer · D | −67,242 | $18.75 | −$1.26M | 0 |
| Ringo William R | Director | Feb 20 | Disposition to Issuer · D | −6,000 | $18.75 | −$113K | 0 |
| Craves Fred B | Director | Feb 20 | Disposition to Issuer · D | −30,000 | $18.75 | −$563K | 0 |
| Craves Fred B | Director | Feb 20 | Disposition to Issuer · D | −65,572 | $18.75 | −$1.23M | 0 |
| Craves Fred B | Director | Feb 20 | Disposition to Issuer · D | −3,441,075 | $18.75 | −$64.5M | 0 |
| Craves Fred B | Director | Feb 20 | Disposition to Issuer · D | −6,000 | $18.75 | −$113K | 0 |
| Bauer Eugene A | Chief Medical Officer | Feb 20 | Disposition to Issuer · D | −16,206 | $18.75 | −$304K | 0 |
| Bauer Eugene A | Chief Medical Officer | Feb 20 | Disposition to Issuer · D | −3,726 | $18.75 | −$69.9K | 0 |
Loading...